ARDELYX, INC.
About ARDELYX, INC.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $407.3M
- Net income
- -$61.6M
- Total assets
- $501.6M
- Market cap
- $1.4B
- Gross margin
- 90.3%
- Operating margin
- -10.1%
- Net margin
- -15.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $407.3M
- Cost of revenue
- $39.5M
- Gross profit
- $367.8M
- Operating expenses
- $408.8M
- Operating income
- -$41.0M
- Income tax
- $969.0K
- Net income
- -$61.6M
- EPS (basic)
- $-0.26
- EPS (diluted)
- $-0.26
Balance sheet
- Total assets
- $501.6M
- Current assets
- $382.3M
- Total liabilities
- $334.7M
- Current liabilities
- $88.6M
- Shareholders’ equity
- $166.9M
Cash flow
- Operating cash flow
- -$42.5M
- Investing cash flow
- -$9.0M
- Financing cash flow
- $54.5M
- Net cash flow
- $3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-0.26
- Shares outstanding
- 247.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 19, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $61.6M in FY2025.
- Revenue grew 3934% from FY2021 to FY2025.
- Gross margin of 90.3%, net margin -15.1%.
- Trading 31% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ARDELYX, INC..
Write a review
News about ARDELYX, INC.
News & sentiment via Polygon.io
